12 January 2024
CVS Group Plc
("CVS" or the "Company")
Exercise of SAYE Options and PDMR Dealing
CVS, one of the UK's leading providers of integrated veterinary services, announces that on 10 January 2024, options over a total of 41,174 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2020 SAYE Plan (2020/2024), at an exercise price of £10.09.
The issuance of shares in connection with the SAYE Exercise was fully satisfied by 41,174 Ordinary Shares held by the CVS Group Employee Benefit Trust (the "EBT"). Following the SAYE Exercise, a total of 6,771 Ordinary Shares are held by the EBT, representing approximately 0.009% of the Company's total voting rights.
Richard Fairman, Chief Executive Officer exercised options over 606 Ordinary Shares in the Company. The balance of the options were exercised by certain other employees and former employees of the Company.
Following his option exercise, Richard Fairman, along with any persons closely associated, holds a beneficial interest in 78,107 Ordinary Shares in the Company, representing approximately 0.109% of the total voting rights of the Company, calculated on the same basis.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Richard Fairman |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification /Amendment | Initial Notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | CVS Group plc |
| b) | LEI | 213800J41XDQ2NX48O05 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.2 pence each
GB00B2863827 | ||||||||||
| b) | Nature of the transaction | Exercise of options under the 2020 SAYE Plan (1 January 2024 maturity)
| ||||||||||
| c) | Price(s) and volume(s) |
| ||||||||||
| d) | Aggregated information
- Aggregated volume
- Price |
N/A - single transaction | ||||||||||
| e) | Date of the transaction | 10 January 2024 | ||||||||||
| f) | Place of the transaction | London Stock Exchange - AIM |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
